Cargando…

Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy

Cardiac shock wave therapy (CSWT) is a novel therapeutic procedure for patients with angina that is refractory to conventional therapy. We investigated the potential mechanism and therapeutic efficacy of non-R-wave-triggered CSWT to attenuate myocardial dysfunction in a large animal model of hyperte...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Fei, Zhen, Zhe, Sun, Si-Jia, Jiang, Yu, Liang, Wei-Hao, Belau, Markus, Storz, Rafael, Liao, Song-Yan, Tse, Hung-Fat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654370/
https://www.ncbi.nlm.nih.gov/pubmed/36362064
http://dx.doi.org/10.3390/ijms232113274
_version_ 1784828914181341184
author Li, Fei
Zhen, Zhe
Sun, Si-Jia
Jiang, Yu
Liang, Wei-Hao
Belau, Markus
Storz, Rafael
Liao, Song-Yan
Tse, Hung-Fat
author_facet Li, Fei
Zhen, Zhe
Sun, Si-Jia
Jiang, Yu
Liang, Wei-Hao
Belau, Markus
Storz, Rafael
Liao, Song-Yan
Tse, Hung-Fat
author_sort Li, Fei
collection PubMed
description Cardiac shock wave therapy (CSWT) is a novel therapeutic procedure for patients with angina that is refractory to conventional therapy. We investigated the potential mechanism and therapeutic efficacy of non-R-wave-triggered CSWT to attenuate myocardial dysfunction in a large animal model of hypertensive cardiomyopathy. Sustained elevated blood pressure (BP) was induced in adult pigs using a combination of angiotensin-II and deoxycorticosterone acetate (DOCA). Two sessions of non-R-wave-triggered CSWT were performed at 11 and 16 weeks. At 10 weeks, systolic and diastolic blood pressure, LV posterior wall thickness and intraventricular septum thickness significantly increased in both the hypertension and CSWT groups. At 20 weeks, +dP/dt and end-systolic pressure-volume relationship (ESPVR) decreased significantly in the hypertension group but not the CSWT group, as compared with week 10. A significant improvement in end-diastolic pressure-volume relationship (EDPVR) was observed in the CSWT group. The CSWT group exhibited significantly increased microvascular density and vascular endothelial growth factor (VEGF) expression in the myocardium. Cytokine array demonstrated that the CSWT group had significantly reduced inflammation compared with the hypertension group. Our results demonstrate that non-R-wave-triggered CSWT is safe and can attenuate LV systolic and diastolic dysfunction via enhancement of myocardial neovascularization and anti-inflammatory effect in a large animal model of hypertensive cardiomyopathy.
format Online
Article
Text
id pubmed-9654370
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96543702022-11-15 Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy Li, Fei Zhen, Zhe Sun, Si-Jia Jiang, Yu Liang, Wei-Hao Belau, Markus Storz, Rafael Liao, Song-Yan Tse, Hung-Fat Int J Mol Sci Article Cardiac shock wave therapy (CSWT) is a novel therapeutic procedure for patients with angina that is refractory to conventional therapy. We investigated the potential mechanism and therapeutic efficacy of non-R-wave-triggered CSWT to attenuate myocardial dysfunction in a large animal model of hypertensive cardiomyopathy. Sustained elevated blood pressure (BP) was induced in adult pigs using a combination of angiotensin-II and deoxycorticosterone acetate (DOCA). Two sessions of non-R-wave-triggered CSWT were performed at 11 and 16 weeks. At 10 weeks, systolic and diastolic blood pressure, LV posterior wall thickness and intraventricular septum thickness significantly increased in both the hypertension and CSWT groups. At 20 weeks, +dP/dt and end-systolic pressure-volume relationship (ESPVR) decreased significantly in the hypertension group but not the CSWT group, as compared with week 10. A significant improvement in end-diastolic pressure-volume relationship (EDPVR) was observed in the CSWT group. The CSWT group exhibited significantly increased microvascular density and vascular endothelial growth factor (VEGF) expression in the myocardium. Cytokine array demonstrated that the CSWT group had significantly reduced inflammation compared with the hypertension group. Our results demonstrate that non-R-wave-triggered CSWT is safe and can attenuate LV systolic and diastolic dysfunction via enhancement of myocardial neovascularization and anti-inflammatory effect in a large animal model of hypertensive cardiomyopathy. MDPI 2022-10-31 /pmc/articles/PMC9654370/ /pubmed/36362064 http://dx.doi.org/10.3390/ijms232113274 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Li, Fei
Zhen, Zhe
Sun, Si-Jia
Jiang, Yu
Liang, Wei-Hao
Belau, Markus
Storz, Rafael
Liao, Song-Yan
Tse, Hung-Fat
Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy
title Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy
title_full Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy
title_fullStr Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy
title_full_unstemmed Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy
title_short Attenuation of Myocardial Dysfunction in Hypertensive Cardiomyopathy Using Non-R-Wave-Synchronized Cardiac Shock Wave Therapy
title_sort attenuation of myocardial dysfunction in hypertensive cardiomyopathy using non-r-wave-synchronized cardiac shock wave therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654370/
https://www.ncbi.nlm.nih.gov/pubmed/36362064
http://dx.doi.org/10.3390/ijms232113274
work_keys_str_mv AT lifei attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy
AT zhenzhe attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy
AT sunsijia attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy
AT jiangyu attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy
AT liangweihao attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy
AT belaumarkus attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy
AT storzrafael attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy
AT liaosongyan attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy
AT tsehungfat attenuationofmyocardialdysfunctioninhypertensivecardiomyopathyusingnonrwavesynchronizedcardiacshockwavetherapy